光荣榜丨中国原创黑色素瘤郭军教授团队历届国际会议大会发言汇总

2022

01/13

e药安全

A-

A+

北京大学肿瘤医院郭军教授团队-中国黑色素瘤原创临床研究阶段汇总。

遇见·肿瘤大咖∣ 郭军：“黑老大”死磕黑色素瘤的血性

2020CSCO丨郭军教授：中国黑色素瘤研究初具蓝图，未来需多中心协同推进

盘点2020｜斯璐：黑色素瘤治疗进展盘点

解码黑色素瘤青年探索者斯璐：她也曾想过放弃

“路漫漫其修远，吾辈青年当上下求索！”——首届CSCO黑色素瘤专委会青委会成立

历史回顾丨中国临床肿瘤学年度研究进展2015-2020黑色素瘤部分重要进展+值得关注的进展回顾

积石成山丨中国黑色素瘤代表性论著阶段总结

读书笔记丨北京大学肿瘤医院郭军教授团队-中国黑色素瘤原创临床研究阶段汇总

● 中国原创黑色素瘤 ●

●●●Original melanoma of China●●●

2005-至今国际会议大会发言（除SMR外）共计8项（其中ASCO 4项，AACR 1项，AACR Melanoma 1项，ESMOAsia 2项）

中国原创黑色素瘤

28591639869378937

国际会议Oral Presentation 2012ASCO: Phase II randomized study of high-dose interferon alfa-2b (HDI)versus chemotherapy as adjuvant therapy in patients with resected mucosal melanoma （8506）

2016ESMOAsia: The natural history and patterns of metastases from mucosal melanoma: an analysis of 706 prospectively-followed patients from china（404O）

2017ESMOAsia: Phase Ic trial of intralesional OrienX010 oncolytic viral therapy into liver metastases among melanoma patients（379O）

2019AACR Melanoma: The landscape of mucosal melanoma：a long way to go 2020ASCO: Overall survival and biomarker analysis of a phase Ib combination study of toripalimab，a humanized IgG4 mAb against programmed death-1（PD-1）with axitinib in patients with metastatic mucosal melanoma （10007） 2021AACR: Safety/tolerability and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with PD-(L)1 refractory/resistant unresectable or metastatic melanoma from a phase 1b study （ CT035） 2021ASCO: Atezolizumab in combination with bevacizumab in patients with unresectable locally advanced or metastatic mucosal melanoma: Interim analysis of an open-label phase II trial （9511） 2021ASCO: A phase 2 clinical trial of neoadjuvant anti-PD-1 ab（Toripalimab）plus axitinib in resectable mucosal melanoma （9512）